The short version
Only one company currently supplies this market — there is no backup if it stumbles.
The numbers behind every sentence are on this page below — and the Watch button emails you when any of them move.
Vitrakvi
Larotrectinib · LAROTRECTINIB 20 mg/mL · Solution · Oral · Loxo Oncology, Inc.
NDC 71777-0392-01 · 100 mL in 1 BOTTLE · NDA · View full market →
Medicare Part D
No Medicare Part D plan in CMS's quarterly files lists this product. That usually means it is discontinued, a repackager's listing, or a product no plan has added to its formulary.
How Part D pricing works →NADAC price per unit
No NADAC pricing on file for this NDC — NADAC covers drugs dispensed by retail community pharmacies.
Supply fragility
Not scored — fragility is computed for NADAC-priced NDCs.
Where it's made
- Penn Pharmaceutical Services LimitedUnited Kingdommanufacture
- Sharp Packaging Services, LLCUnited Stateslabel · pack
- W. R. Grace & Co.-Conn.United Statesapi manufacture
Establishments this product's FDA label declares, located via FDA registration data. How we built this →
Is this a "specialty" drug?
There's no legal definition — it meets 1 of 6 public criteria. Why that matters →
- Part D specialty tier
- Costs ≥ $950/fill · avg $37,105.59 per prescription
- Biologic (BLA)
- Injectable / infused
- Orphan-drug exclusivity
- REMS program
Regulatory
- Application
- NDA211710
- TE code
- —
- Approval date
- Nov 26, 2018
- Patents / exclusivity
- 18 patents, 0 exclusivities
| Type | Number / code | Expires |
|---|---|---|
| patent | 11337967 | May 16, 2037 |
| patent | 11974998 | May 16, 2037 |
| patent | 10668072 | Apr 4, 2037 |
| patent | 10137127 | Apr 4, 2037 |
| patent | 11484535 | Apr 4, 2037 |
| patent | 11191766 | Apr 4, 2037 |
| patent | 10045991 | Apr 4, 2037 |
| patent | 10799505 | Aug 15, 2036 |
| patent | 9782414 | Nov 16, 2035 |
| patent | 10172861 | Nov 16, 2035 |
| patent | 8513263 | Dec 23, 2029 |
| patent | 9127013 | Oct 21, 2029 |
Shortage history
No FDA shortage reports for this drug or its presentations.
Recalls (this NDC)
No enforcement reports list this package NDC.
Manufacturers of Larotrectinib (Solution)
| Labeler | Strength | First seen | Last seen |
|---|---|---|---|
| Loxo Oncology, Inc. | LAROTRECTINIB 20 mg/mL | Jul 15, 2026 | Sep 2, 2026 |
Roster from daily NDC Directory diffs — first/last seen dates start July 2026.
Cite this page
DrugDashboards, "Vitrakvi — NDC 71777-0392-01," retrieved September 3, 2026, https://drugdashboards.com/drug/71777039201.
Free to cite with attribution — see how the data is put together.